Physician profile
David S Fefferman
NPI 1720015928
$3,386.77
in general payments reported to CMS, 2019-2025
28 companies · $545 in 2025
The $545 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $269 · 2021: $333 · 2023: $216 · 2024: $692 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407 · Education: $46.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.58 |
| Education | $46.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $592.68 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $426.64 | 2019-2021 | |
| Pfizer INC. | $271.70 | 2019-2025 | |
| Genzyme Corporation | $270.64 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $265.44 | 2019-2025 | Entyvio |
| Celgene Corporation | $218.21 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $173.03 | 2019-2025 | Simponi Aria, Tremfya, Stelara |
| Gilead Sciences, INC. | $165.32 | 2019-2025 | |
| Boston Scientific Corporation | $137.39 | 2024 | Spyglass |
| Ucb, INC. | $115.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $100.92 | 2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $81.56 | 2019-2023 | Rebyota |
| Qol Medical, LLC | $65.23 | 2021-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $61.09 | 2019-2024 | |
| Shionogi INC | $53.61 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.87 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $42.26 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $38.88 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $36.15 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $32.86 | 2021-2023 | |
| Allergan, INC. | $32.48 | 2019-2020 | |
| Madrigal Pharmaceuticals | $28.76 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $24.73 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $23.83 | 2025 | Zenpep |
| Organon LLC | $22.39 | 2025 | Hadlima |
| Concordia Pharmaceuticals INC. | $21.86 | 2019 | |
| Ardelyx, INC. | $21.26 | 2023 | Ibsrela |
| Shire North American Group INC | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fefferman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.